NCT06016517
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
At risk: Primary completion moved 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 5 more changesShow less
- Start date: Sep 1, 2026 to Dec 1, 2026
- Eligibility criteria expanded, about 35 words
- Primary completion pushed from Sep 1, 2028 to Dec 1, 2028
- Study description expanded, about 7 words
- Site details revised
- Notable Primary completion pushed from Dec 15, 2027 to Sep 1, 2028
- Start date: May 1, 2026 to Sep 1, 2026
- Study completion date: Dec 1, 2028 to Dec 15, 2028
- Notable Start date: Mar 15, 2026 to May 1, 2026
- Primary completion pushed from Aug 15, 2027 to Dec 15, 2027
- Notable Start date: Nov 15, 2025 to Mar 15, 2026v10
- Notable Start date: Aug 15, 2025 to Nov 15, 2025v9
Show 7 earlier versionsHide 7 earlier versions
- Notable Eligibility criteria expanded, about 121 words
- Secondary endpoints: 7 to 6
- Study description expanded, about 57 words
- Study title expanded, about 7 words
- Notable Primary completion date: May 15, 2026 to Aug 15, 2027
- Start date: May 15, 2025 to Aug 15, 2025
- Study completion date: Dec 1, 2026 to Dec 1, 2028
- Notable Primary completion date: Jul 1, 2025 to May 15, 2026
- Start date: Oct 1, 2024 to May 15, 2025
- Study completion date: Oct 1, 2025 to Dec 1, 2026
Notable Start date: Jul 1, 2024 to Oct 1, 2024v5 Show 5 more changesShow less
- Eligibility criteria expanded, about 21 words
- Study completion date: Jul 1, 2025 to Oct 1, 2025
- Interventions: Adalimumab (Drug), Sarilumab (Drug), Upadacitinib (Drug) to Adalimumab (Drug), Etanercept (Drug), Tocilizumab (Drug), Upadacitinib (Drug)
- Secondary endpoints: details revised at 1 of 7 entries
- Study description shortened, about 2 words
- Notable Start date: May 15, 2024 to Jul 1, 2024
- Primary and study completion dates: May 15, 2025 to Jul 1, 2025
- Notable Start date: Jan 1, 2024 to May 15, 2024
- Primary and study completion dates: Jan 1, 2025 to May 15, 2025
- Notable Start date: Oct 1, 2023 to Jan 1, 2024
- Primary completion date: Oct 1, 2024 to Jan 1, 2025
- Study completion date: Oct 1, 2025 to Jan 1, 2025
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change in Disease Activity Score (DAS) 28
Timeframe: Baseline and week 12 of each treatment period
Secondary (6)
Change in The Routine Assessment of Patient Index Data 3 (RAPID3)
Change in American College of Rheumatology 20 (ACR20)
Change in American College of Rheumatology 50 (ACR50)
Change in American College of Rheumatology 70 (ACR70)
The Medical Outcome Study Short-Form 12- item Health Survey (SF-12)
Show 1 moreShow less
Treatment Burden Questionnaire (TBQ)
Arms and interventions
Drugs: Etanercept, Adalimumab, Upadacitinib, Tocilizumab
Sites
1 site in 1 country
- Tufts Medical CenterBoston, Massachusetts, United States